Human Metapneumovirus (hMPV) Therapeutics Market Report 2026

Human Metapneumovirus (hMPV) Therapeutics Market Overview

• Human Metapneumovirus (hMPV) Therapeutics market size has reached to $0.7 billion in 2025 • Expected to grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Respiratory Infections Fueling Growth of the Human Metapneumovirus (hMPV) Therapeutics Market Due To Increasing Vulnerability Among Key Populations • Market Trend: Development Of Targeted Antiviral Therapies In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Metapneumovirus (hMPV) Therapeutics Market?

Human metapneumovirus (hMPV) therapeutics refers to the medical treatments and interventions aimed at managing and alleviating the symptoms caused by human metapneumovirus, a respiratory virus that commonly affects infants, older people, and immunocompromised individuals. The therapeutics work by inhibiting viral replication, blocking viral entry into host cells, and modulating the immune response to reduce inflammation and disease severity. The main drug classes for human metapneumovirus (hMPV) therapeutics include antipyretics, decongestants, cough suppressants, and other drug classes. An antipyretic is a substance that reduces fever by lowering the body's temperature through its action on the hypothalamus. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They are used across multiple end-use settings such as hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, and other healthcare facilities.

What Is The Human Metapneumovirus (hMPV) Therapeutics Market Growth Forecast?

The human metapneumovirus (hmpv) therapeutics market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to rising focus on developing virus-specific therapeutics, increasing investment in respiratory virus research, growing demand for effective treatments in immunocompromised populations, expansion of clinical trials for novel antiviral agents, increasing preparedness for seasonal respiratory virus outbreaks. Major trends in the forecast period include increasing focus on targeted antiviral therapies for respiratory viruses, rising demand for symptom-based management in pediatric and geriatric patients, growing emphasis on early intervention for high-risk populations, expansion of supportive care therapeutics for viral respiratory infections, increasing clinical research into novel hmpv treatment options.

Global Human Metapneumovirus (hMPV) Therapeutics Market Segmentation

1) By Drug Class: Antipyretic, Decongestants, Cough Suppressants, Other Drug Classes 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End-Use: Hospitals And Clinics, Academic And Research Institutions, Other End-Uses Subsegments: 1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol) 2) By Decongestants: Nasal Decongestants, Oral Decongestants 3) By Cough Suppressants: Dextromethorphan, Benzonatate 4) By Other Drug Classes: Antiviral Agents, Inhaled Corticosteroids

What Is The Driver Of The Human Metapneumovirus (hMPV) Therapeutics Market?

The increasing prevalence of respiratory infections is expected to propel the growth of the human metapneumovirus (HMPV) therapeutics market going forward. Respiratory infections are illnesses that affect the respiratory tract, which includes the nose, throat, airways, and lungs. The increasing number of respiratory infections is due to rising air pollution levels. Pollutants like particulate matter and nitrogen dioxide irritate and weaken the respiratory tract, making individuals more susceptible to infections. Human metapneumovirus (hMPV) therapeutics are essential for treating respiratory infections caused by hMPV by reducing viral replication and inflammation through antiviral treatments and supportive care, ultimately improving health outcomes for vulnerable groups such as infants, the elderly, and immunocompromised patients. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, Australia Chronic Obstructive Pulmonary Disease (COPD), contributed to 3.6% of the total disease burden in 2023. It accounted for 50% of the overall burden from respiratory conditions, with an estimated 638,000 people (2.5% of the population) living with COPD in 2022. Therefore, the increasing prevalence of respiratory infections drives growth in the human metapneumovirus (HMPV) therapeutics industry.

Key Players In The Global Human Metapneumovirus (hMPV) Therapeutics Market

Major companies operating in the human metapneumovirus (hmpv) therapeutics market are Pfizer Inc., Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc., Enanta Pharmaceuticals Inc.

Global Human Metapneumovirus (hMPV) Therapeutics Market Trends and Insights

Major companies operating in the human metapneumovirus (hMPV) therapeutics market focus on developing targeted antiviral therapies, such as monoclonal antibodies, to effectively combat hMPV infections. Monoclonal antibodies (mAbs) are laboratory-made proteins that mimic the immune system's natural ability to fight diseases. Monoclonal antibodies provide targeted therapy for various diseases, including cancer and autoimmune disorders, by specifically binding to and neutralizing harmful antigens or cells. For instance, in October 2024, Vicebio Ltd., a UK-based biopharmaceutical company, secured $100 million in Series B financing, led by TCGX with participation from Goldman Sachs Alternatives and others, to advance its next-generation respiratory virus vaccines. The funding supports the Phase 1 clinical trial of VXB-241, a bivalent vaccine targeting RSV and hMPV, with initial results expected in mid-2025. It will also accelerate the development of VXB-251, a trivalent vaccine targeting RSV, hMPV, and Parainfluenza Virus 3, to address significant medical burdens in older people.

What Are Latest Mergers And Acquisitions In The Human Metapneumovirus (hMPV) Therapeutics Market?

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Icosavax, Inc., for $1.1 billion. With this acquisition, AstraZeneca aims to strengthen its vaccine and respiratory infection portfolio by integrating Icosavax’s innovative virus-like particle (VLP) technology and its potential first-in-class combination vaccine candidate for RSV and hMPV. Icosavax, Inc. is a US-based biopharmaceutical company developing virus-like particle vaccines, including a potential first-in-class combination vaccine for RSV and hMPV.

Regional Outlook

North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Metapneumovirus (hMPV) Therapeutics Market?

The human metapneumovirus (hMPV) therapeutics market consists of revenues earned by entities providing services such as antiviral drug development, vaccine research, diagnostic testing, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus (hMPV) therapeutics market also includes sales of antiviral medications, immunotherapies, vaccines, and related diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Metapneumovirus (hMPV) Therapeutics Market Report 2026?

The human metapneumovirus (hmpv) therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus (hmpv) therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.